Mucosal administration of IL-10 enhances oral tolerance in autoimmune encephalomyelitis and diabetes

International Immunology

Volumn 13, Issue 6, 2001, Pages 825-833

  Slavin, A J ^a   Maron, R ^a   Weiner, H L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Autoimmunity; IL 10; Mucosa; Tolerance

Indexed keywords

AUTOANTIGEN; CYTOKINE; GAMMA INTERFERON; INSULIN; INTERLEUKIN 10; INTERLEUKIN 2; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; OVALBUMIN; TRANSFORMING GROWTH FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; IMMUNOREGULATION; IN VITRO STUDY; INCIDENCE; LYMPHOCYTE PROLIFERATION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; RELAPSE; TH1 CELL;

EID: 0034991196     PISSN: 09538178     EISSN: None     Source Type: Journal    
DOI: 10.1093/intimm/13.6.825     Document Type: Article

References (59)

1. Oral tolerance: Mechanisms and therapeutic applications
2. Peripheral deletion of antigen-reactive T-cells in oral tolerance
3. Oral tolerance in experimental autoimmune encephalomyelitis. III. Evidence for clonal anergy
4. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage
5. Regulatory T-cell clones induced by oral tolerance: Suppression of autoimmune encephalomyelitis
6. Mucosal immunity to HIV-1: Systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN (A)
7. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL-4-producing cells
8. Differential regulation of T helper phenotype development by interleukin 4 and 10 in αβ T-cell-receptor transgenic system
9. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis
10. + T-cells: IL-4 and IFN-γ have opposing effects, while TGF-β positively regulates its own production
11. h3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis
12. Orally induced immune responsiveness is abrogated by IFN-γ treatment
13. High dose oral tolerance in ovalbumin TCR-transgenic mice: Systemic neutralization of IL-12 augments TGF-β secretion and T-cell apoptosis
14. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease
15. Oral cytokine administration
16. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis
17. Effect of oral beta interferon on subsequent immune responsiveness
18. Nasal administration of multiple antigens suppresses experimental autoimmune myasthenia gravis, encephalomyelitis and neuritis
19. Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats
20. IL-10 prevents experimental allergic encephalomyelitis in rats
21. IL-10 fails to abrogate experimental autoimmune encephalo-myelitis
22. + T cells, but not B cells, mediate colitis in interleukin 10-deficient mice
23. Large scale preparation of myelin basic protein from central nervous tissue of several mammalian species
24. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
25. Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment
26. h2-type responses in NOD mice
27. Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice
28. Parasite induced protection from experimental autoimmune encephalomyelitis
29. Cholera toxin B subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance
30. Oral antigen delivery by way of a multiple emulsion system enhances oral tolerance
31. Anti-IL-10 treatment does not block either the induction or the maintenance of orally induced tolerance to OVA
32. The preventive effect of oral administration of type I interferon on collagen-induced arthritis in rats
33. Suppression of relapsing EAE in the SJL/J mouse by oral administration of type I interferons
34. Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis
35. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T-cell epitope
36. Protection of nonobese diabetic mice from diabetics by intranasal or subcutaneous administration of insulin peptide B-(9-23)
37. Aerosol insulin induces regulatory CD8 γδ T-cells that prevent murine insulin-dependent diabetes
38. h2 responses and prevents murine insulin-dependent diabetes
39. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: Influence of MHC binding affinity
40. Antigen-driven peripheral immune tolerance: Suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen
41. Nasal lymphoid tissue (NALT) as a mucosal immune inductive site
42. Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): Induction of protective tolerance in primed animals
43. Cellular mRNA expression of interferon-gamma (IFN-γ), IL-4 and transforming growth factor-beta (TGF-β) in rats nasally tolerized against experimental autoimmune myasthenia gravis (EAMG)
44. Interleukin-10: An anti-inflammatory cytokine with therapeutic potential
45. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery
46. IL-10 is critical in the regulation of autoimmune encephalomyelitis as demonstrated by studies of IL-10- and IL-4-deficient and transgenic mice
47. Mucosal tolerance: A two-edged sword to prevent and treat autoimmune diseases
48. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T-cells
49. An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease
50. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse
51. Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation
52. Alpha/beta-T cell receptor (TCR) (+) CD4 (-) (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/LT mice by the influence of interleukin (IL)-4 and/or IL-10
53. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of b cells in nonobese diabetic mice
54. Expression of IL-10 receptor on human intestinal epithelial cells and its functional consequences
55. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease
56. Interleukin 10 modulates ion transport in rat small intestine
57. Induction of tolerance by IL-10-treated dendritic cells
58. + T-cells to secrete interleukin-4
59. Effect of interleukin-10 on dendritic cell maturation and function